मूलभूत आँकड़े
| LEI | 529900S3ZI14OWRJII50 |
| CIK | 1178670 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Alnylam Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| July 31, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Mill |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 (June 12, 2025) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| June 18, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer − R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics – − Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030 – CAMBRID |
|
| May 22, 2025 |
Confidential Treatment Requested by Alnylam Pharmaceuticals, Inc. Pursuant to 17 C.F.R. Section 200.83 FOIA Confidential Treatment Request The entity requesting confidential treatment is: Alnylam Pharmaceuticals, Inc. 675 West Kendall Street, Henri A. Termeer Square Cambridge, MA 02142 Attention: Jeffrey V. Poulton May 22, 2025 VIA EDGAR AND ELECTRONIC MAIL Securities and Exchange Commission Divis |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 (May 8, 2025) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identifica |
|
| May 13, 2025 |
Certificate of Amendment to Restated Certificate of Incorporation of Alnylam Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”) does hereby certify: 1.Pursuant to Section 242 of the DGCL, this Certificate of Amendment to Restated Certificat |
|
| May 1, 2025 |
Performance Stock Unit Award Agreements Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ALNYLAM PHARMACEUTICALS, INC. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee: %% |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 1, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven |
|
| May 1, 2025 |
Amended and Restated 2018 Stock Ince Exhibit 10.1 ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Unit Award Agreement for Non-employee Directors (“Agreement”) Granted Under the Amended and Restated 2018 Stock Incentive Plan Name of Grantee: %%FIRSTNAME%-% %%LASTNAME%-% No. of Restricted Stock Units: %%TOTALSHARESGRANTED,’999,999,999’%-% Grant Date: %%OPTIONDATE,’Month DD, YYYY’%-% Pursuant to the Alnylam Pharmaceuticals, Inc. Amended |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICA |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 24, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 21, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) − Novel Mecha |
|
| March 21, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 67 |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 (March 3, 2025) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| March 5, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary CAMBRIDGE, Mass., March 5, 2025 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today anno |
|
| February 13, 2025 |
he Registrant, dated February 27, 202 Exhibit 19.1 ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY (Amended as of February 27, 2023) 1.BACKGROUND AND PURPOSE The federal securities laws prohibit any member of the Board of Directors (a “Director”) or employee of Alnylam Pharmaceuticals, Inc. and its subsidiaries (collectively, the “Company”) from purchasing or selling Company securities on the basis of materia |
|
| February 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 13, 2025 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Ownership Percentage Jurisdiction of Organization Alnylam U.S., Inc. 100% Delaware Alnylam U.S. Holdings, Inc. 100% Delaware Alnylam UK Holdings Ltd. 100% United Kingdom Alnylam Securities Corporation 100% Massachusetts Sirna Therapeutics, Inc. 100% Delaware Alnylam Argentina SRL 95% Argentina Alnylam Australia Pty Ltd. 100% Australia Alnylam Austri |
|
| February 13, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress − Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Re |
|
| January 13, 2025 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals – Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTR |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 (January 12, 2025) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer I |
|
| November 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Alnylam Pharmaceuticals, Inc. |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| October 31, 2024 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year-Over-Year Growth Compared to Q3 2023, Drive |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEU |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 31, 2024 |
Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 3 to the Master Agreement This Amendment No. 3 (“Amendment No. 3”) to the Master Agreement is entered into and effective as of August 1, 20 |
|
| August 22, 2024 |
August 22, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 1, 2024 |
Exhibit 10.4 ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2018 Stock Incentive Plan Participant: [ ] ID: [ ] Award Number: [ ] Exercise Price Per Share: [ ] Grant Date: [ ] Vesting Commencement Date: [ ] Expiration Date: [ ] Number of Shares/Units: [ ] 1.Grant of Option. This Nonstatutory Stock Option Agreement (“Agreement”) evidences the grant by Alnylam Pharmac |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| August 1, 2024 |
Exhibit 10.2 ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee: [ ] No. of Restricted Stock Units: [ ] Grant Date: [ ] Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of |
|
| August 1, 2024 |
Exhibit 10.1 ALNYLAM PHARMACEUTICALS, INC. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee: [ ] No. of Performance Stock Units: [ ] Grant Date: [ ] Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number |
|
| August 1, 2024 |
Exhibit 10.3 ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2018 Stock Incentive Plan Participant: [ ] ID: [ ] Award Number: [ ] Exercise Price Per Share: [ ] Grant Date: [ ] Vesting Commencement Date: [ ] Expiration Date: [ ] Number of Shares/Units: [ ] 1.Grant of Option. This Nonstatutory Stock Option Agreement (“Agreement”) evidences the grant by Alnylam Pharmac |
|
| August 1, 2024 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved Second Quarter 2024 Global Net Product Revenues of $410 Million, Representing 34% Year-Over-Year Growth Compared to Q2 2023, Dri |
|
| May 20, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 (May 16, 2024) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identific |
|
| May 2, 2024 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth – − Demonstrated Strong Progress with Zilebesiran Hypertension P |
|
| May 2, 2024 |
Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 2 to the Master Agreement This Amendment No. 2 (“Amendment No. 2”) to the Master Agreement is entered into and effective as of March 7, 202 |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICA |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 1, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 675 |
|
| March 4, 2024 |
Exhibit 10.1 February 8, 2024 Indrani Franchini at the address on file with Alnylam Pharmaceuticals, Inc. Dear Indrani, This letter agreement is to summarize the terms of the separation package to which you and Alnylam Pharmaceuticals, Inc. (the “Company”) have agreed. Please read this letter agreement, which includes a general release (this “Letter Agreement”), carefully. If you are willing to ag |
|
| February 15, 2024 |
EXHIBIT 97 ALNYLAM PHARMACEUTICALS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION I.BACKGROUND Alnylam Pharmaceuticals, Inc. (the “Company”) has adopted this policy (this “Policy”) to provide for the recovery or “clawback” of certain incentive compensation in the event of a Restatement. This Policy is intended to comply with, and will be interpreted to be consist |
|
| February 15, 2024 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − Company Announces Updated Statistical Analysis Plan and Timing for HELIOS-B Phase 3 Study |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Comm |
|
| February 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM |
|
| February 15, 2024 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Ownership Percentage Jurisdiction of Organization Alnylam U.S., Inc. 100% Delaware Alnylam Securities Corporation 100% Massachusetts Sirna Therapeutics, Inc. 100% Delaware Alnylam Austria GmbH 100% Austria Alnylam Belgium SPRL/BVBA 100% Belgium Alnylam Brasil Farmaceutica Ltda. 99% Brazil Alnylam (Bermuda) Ltd. 100% Bermuda Alnylam Canada ULC 100% C |
|
| February 13, 2024 |
ALNY / Alnylam Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Alnylam Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 02043Q107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 9, 2024 |
ALNY / Alnylam Pharmaceuticals, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 29, 2024 |
ALNY / Alnylam Pharmaceuticals, Inc. / BAILLIE GIFFORD & CO Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALNYLAM PHARMACEUTICALS (Amendment No.4) - (Name of Issuer) Common Stock - (Title of Class of Securities) 02043Q107 - (CUSIP Number) 29 December 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 (January 12, 2024) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer I |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 (January 7, 2024) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ide |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates – Achieved Full Year 2023 Preliminary Global Net Product Revenues of $1,241 Million for ONPATTRO®, AMVUTTRA®, GIVL |
|
| November 2, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT by and between ALNYLAM PHARMACEUTICALS, INC. on the one hand and F. Hoffmann-La Roche Ltd. and Genentech, Inc. on the other hand. EFFECTIVE DATE: |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commi |
|
| November 2, 2023 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 – − Received Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEU |
|
| October 10, 2023 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis – FDA Cites Insufficient Evidence of Clinical Meaningfulness |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 (October 9, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Id |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 (September 26, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employ |
|
| August 3, 2023 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity – Achieved Second Quarter 2023 Global Net Product Revenues of $306 Million, Representing 43% Year-Over-Year Growth Compared to Q2 2 |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 (July 31, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identi |
|
| August 3, 2023 |
EX-10.1 Exhibit 10.1 July 31, 2023 Akshay K. Vaishnaw, M.D., Ph.D. at the address on file with Alnylam Pharmaceuticals, Inc. Dear Akshay: This letter (this “Letter Agreement”) sets forth the terms of your employment, effective October 2, 2023 (the “Effective Date”), as Chief Innovation Officer of Alnylam Pharmaceuticals, Inc. (the “Company”). 1. Service as Chief Innovation Officer As Chief Innovat |
|
| August 3, 2023 |
Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 1 to the Master Agreement This Amendment No. 1 (“Amendment No. 1”) to the Master Agreement is entered into and effective as of April 10, 20 |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2023 (July 21, 2023) Alnylam Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36407 77-0602661 (State or other jurisdiction of incorp |
|
| July 26, 2023 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk – Partnership Combines Alnylam’s |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 (June 30, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| June 30, 2023 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis CAMBRIDGE, Mass. — June 30, 2023 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), t |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 (May 18, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identific |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICA |
|
| May 4, 2023 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 – − Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid A |
|
| May 4, 2023 |
Exhibit 10.2 ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee: [ ] No. of Restricted Stock Units: [ ] Grant Date: [ ] Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission |
|
| May 4, 2023 |
Exhibit 10.1 ALNYLAM PHARMACEUTICALS, INC. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee: [ ] No. of Performance Stock Units: [ ] Grant Date: [ ] Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number |
|
| April 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 3, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 (March 7, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| February 23, 2023 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity − Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021 (43% Using Constant Exchange Rate*) – − Submitted and Received Acceptance of Supplemental New Dr |
|
| February 23, 2023 |
EX-FILING FEES Exhibit 107.1 Table 1. Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share Other(2) 6,000,000 shares(3) $201.42 $1,208,520,000.00 $0.000110 |
|
| February 23, 2023 |
Power of Attorney (included on the signature page of this registration statement). As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Ownership Percentage Jurisdiction of Organization Alnylam U.S., Inc. 100% Delaware Alnylam Securities Corporation 100% Massachusetts Sirna Therapeutics, Inc. 100% Delaware Alnylam Austria GmbH 100% Austria Alnylam Belgium SPRL/BVBA 100% Belgium Alnylam Brasil Farmaceutica Ltda. 99% Brazil Alnylam (Bermuda) Ltd. 100% Bermuda Alnylam Canada ULC 100% C |
|
| February 23, 2023 |
EXECUTION COPY Exhibit 10.41 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. CROSS-LICENSE AGREEMENT By and Among ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION And PROTIVA BIOTHERAPEUTICS INC. Dated: November 12, 2012 TABLE OF CONTENTS ARTICLE I - DEFINITIONS 2 ARTICLE II - LICENSE GRANTS AND RE |
|
| February 23, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM |
|
| February 23, 2023 |
Exhibit 10.60 AMENDMENT TO PURCHASE AND SALE AGREEMENT This AMENDMENT TO PURCHASE AND SALE AGREEMENT (this “Amendment”) is effective as of October 31, 2022 and is between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Seller”), and BX Bodyguard Royalties L.P., a Delaware limited partnership (the “Purchaser”). W I T N E S S E T H : WHEREAS, the Seller and Purchaser are parties to that |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Comm |
|
| February 23, 2023 |
EXHIBIT 10.46 LICENSE AND COLLABORATION AGREEMENT by and between ALNYLAM PHARMACEUTICALS, INC. and THE MEDICINES COMPANY CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE |
|
| February 23, 2023 |
Exhibit 10.48 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO LICENSE AND COLLABORATION AGREEMENT THIS AMENDMENT NO. 2 TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), effective as of O |
|
| February 13, 2023 |
ALNY / Alnylam Pharmaceuticals, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 9, 2023 |
ALNY / Alnylam Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Alnylam Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 02043Q107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 (January 8, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ide |
|
| January 9, 2023 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates – Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 (January 5, 2023) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ide |
|
| January 6, 2023 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Updates to its Board of Directors - Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies ? - Michael W. Bonney Steps Down as Executive Cha |
|
| October 27, 2022 |
Exhibit 4.1 ALNYLAM PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of September 15, 2022 1.00% Convertible Senior Notes due 2027 TABLE OF CONTENTS PAGE ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 15 ARTICLE 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designation and Amount 15 Sect |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEU |
|
| October 27, 2022 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO® – − Strong First Full Quarter of AMVUTTRA in U.S.: Achieving $25 Million in Net Product Revenues and Driving 30% U.S. Total TTR Growth Compared with Q2 2022 |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commi |
|
| September 16, 2022 |
Exhibit 4.1 EXECUTION VERSION ALNYLAM PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of September 15, 2022 1.00% Convertible Senior Notes due 2027 TABLE OF CONTENTS PAGE ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 15 ARTICLE 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designation |
|
| September 16, 2022 |
Exhibit 10.1 [Insert Dealer Name] [Insert Dealer Address] DATE: September [ ], 2022 TO: Alnylam Pharmaceuticals, Inc. 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 FROM: [Insert Dealer Name] SUBJECT: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transa |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 (September 12, 2022) Alnylam Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction |
|
| September 13, 2022 |
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes CAMBRIDGE, Mass. ? September 12, 2022 ? Alnylam Pharmaceuticals, Inc. (?Alnylam?) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has |
|
| September 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 (September 12, 2022) Alnylam Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction |
|
| September 13, 2022 |
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes Exhibit 99.2 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes CAMBRIDGE, Mass. ? September 13, 2022 ? Alnylam Pharmaceuticals, Inc. (?Alnylam?) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the prici |
|
| September 9, 2022 |
ALNY / Alnylam Pharmaceuticals, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 (August 19, 2022) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ide |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commissi |
|
| July 28, 2022 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity ? Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO?, GIVLAARI?, and OXLUMO? (33% Growth vs. Same Period Last Year) ? ? Received FDA Approval of AMVUTTRA? (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediate |
|
| July 28, 2022 |
Exhibit 10.1 ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2018 STOCK INCENTIVE PLAN 1.Purpose The purpose of this Amended and Restated 2018 Stock Incentive Plan (the ?Plan?) of Alnylam Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expec |
|
| June 14, 2022 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces FDA Approval of AMVUTTRA? (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults ? First and Only FDA-approved Treatment Demonstrating Reversal in Neur |
|
| June 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 (June 13, 2022) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| May 23, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 (May 18, 2022) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identific |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commiss |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICA |
|
| April 28, 2022 |
Letter Agreement between the Registrant and Exhibit 10.1 January 14, 2022 Indrani Franchini [**] Dear Indrani, I am pleased to offer you the position of EVP, Chief Legal Officer and Secretary with Alnylam Pharmaceuticals, Inc. (?Alnylam? or the ?Company?) reporting to Yvonne Greenstreet, Alnylam?s Chief Executive Officer. Base Salary You will receive a bi-weekly salary of $22,307.69, equivalent to $580,000.00 annually. The Company currently |
|
| April 28, 2022 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity ? Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO?, GIVLAARI?, and OXLUMO? ? ? Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy ? ? Announced 3-Month Extension of Re |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 (March 31, 2022) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identi |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 5, 2022 |
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors CAMBRIDGE, Mass., ? April 5, 2022 ? Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from th |
|
| April 5, 2022 |
DEF 14A 1 d312403ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| April 4, 2022 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran ? New PDUFA goal date scheduled for July 14, 2022, due to amendment to address pending inspection classification at third-party secondary packaging and la |
|
| April 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 4, 2022 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 675 West Kendall Street, Henri A. Ter |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 67 |
|
| February 10, 2022 |
Exhibit 10.12 ALNYLAM PHARMACEUTICALS, INC. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee: [ ] No. of Performance Stock Units: [ ] Grant Date: [ ] Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the ?Plan?), Alnylam Pharmaceuticals, Inc. (the ?Company?) hereby grants an award of the number |
|
| February 10, 2022 |
Exhibit 10.70 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO CO-DEVELOPMENT AGREEMENT This AMENDMENT NO. 1 TO CO-DEVELOPMENT AGREEMENT (this ?Amendment?) is entered into as of November 23, 2021 (the ?Effective Date?), by and between Alnylam Pharmaceut |
|
| February 10, 2022 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Ownership Percentage Jurisdiction of Organization Alnylam U.S., Inc. 100% Delaware Alnylam Securities Corporation 100% Massachusetts Sirna Therapeutics, Inc. 100% Delaware Alnylam Austria GmbH 100% Austria Alnylam Belgium SPRL/BVBA 100% Belgium Alnylam Brasil Farmaceutica Ltda. 99% Brazil Alnylam (Bermuda) Ltd. 100% Bermuda Alnylam Canada ULC 100% C |
|
| February 10, 2022 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity ? Achieved Fourth Quarter and Full Year 2021 Global Net Product Revenues of $199 Million and $662 Million, Respectively, Representing 83% Annual Growth Compared to 2020 ? ? Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloi |
|
| February 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No |
|
| February 10, 2022 |
Exhibit 10.11 ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2018 Stock Incentive Plan Participant: [ ] ID: [ ] Award Number: [ ] Exercise Price Per Share: [ ] Grant Date: [ ] Vesting Commencement Date: [ ] Expiration Date: [ ] Number of Shares/Units: [ ] 1.Grant of Option. This Nonstatutory Stock Option Agreement (?Agreement?) evidences the grant by Alnylam Pharma |
|
| February 9, 2022 |
ALNY / Alnylam Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Alnylam Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 02043Q107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 10, 2022 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates ? Achieved Full Year 2021 Preliminary Global Net Product Revenues of $662 Million, Representing 83% Annual Growth Compared |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 (January 9, 2022) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Id |
|
| January 4, 2022 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President ? Consistent Scientific Leadership Focused on Sustainable Innovation ? CAMBRIDGE, Mass., January 4, 2022 ? Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 4, 2022 Alnylam Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 (December 14, 2021) Alnylam Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction o |
|
| December 20, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is effective as of the 14th day of December 2021 by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Dr. Yvonne L. Greenstreet, MBChB, MBA (the ?Executive?). 1. Purpose. The Company considers it in the best interests of its stockholders to promote and preserve the continuous employment o |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEU |
|
| October 28, 2021 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity - Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ONPATTRO?, GIVLAARI?, and OXLUMO? ? - Reported Positive Topl |
|
| October 28, 2021 |
Exhibit 10.1 September 6, 2021 Laurie B. Keating, at the address on file with Alnylam Pharmaceuticals, Inc. Dear Laurie: In connection with your retirement as Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc. (the ?Company?), this letter agreement (the ?Letter Agreement?) sets forth the terms of your retirement and your transition to providing consulting |
|
| October 28, 2021 |
Exhibit 99.2 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Planned CEO Leadership Transition - Founding Alnylam CEO John Maraganore to Transition CEO Leadership to Alnylam President Yvonne Greenstreet at Year End ? CAMBRIDGE, Mass., ? October 28, 2021 ? Alnylam Pharmaceuticals, Inc. (Nas |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 (October 26, 2021) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Inco |
|
| October 28, 2021 |
EX-10.1 2 d240930dex101.htm EX-10.1 Exhibit 10.1 October 26, 2021 John M. Maraganore, Ph.D., at the address on file with Alnylam Pharmaceuticals, Inc. Dear John: In connection with your retirement as Chief Executive Officer of Alnylam Pharmaceuticals, Inc. (the “Company”), this letter agreement (the “Letter Agreement”) sets forth the terms of your retirement and your transition to providing consul |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 (September 6, 2021) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of In |
|
| August 3, 2021 |
, Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics, Inc., Exhibit 10.4 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Alnylam – Tekmira – Protiva – UBC – AlCana Supplemental Agreement Effective July 27, 2009 This Supplemental Agreement is made by and among Alnylam Pharma |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| August 3, 2021 |
Exhibit 10.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 28th day of April, 2021, by and between BMR-FRESH POND RESEARCH PARK LLC, a Delaware limited liability company (?Landlord?), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of Feb |
|
| August 3, 2021 |
Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009 EX-10.3 4 alny2021q210-qex103.htm EX-10.3 Exhibit 10.3 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT THIS AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT (this “Ame |
|
| August 3, 2021 |
Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity ? Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO?, GIVLAARI?, and OXLUMO? ? ? Advanced Vutrisiran |
|
| August 3, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is effective as of the 2nd day of August 2021 by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and John M. Maraganore, Ph.D. (the ?Executive?). 1. Purpose. The Company considers it in the best interests of its stockholders to promote and preserve the continuous employment of key managemen |
|
| August 3, 2021 |
Sponsored Research Agreement dated as of July 27, 2009 by and among the Exhibit 10.2 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SPONSORED RESEARCH AGREEMENT THIS SPONSORED RESEARCH AGREEMENT (together with the attached Exhibits, the ?Agreement?), dated as of July 27, 2009 (the ?Ef |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 (August 2, 2021) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorpor |
|
| May 21, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 (May 18, 2021) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporatio |
|
| April 29, 2021 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity ? Achieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO?, GIVLAARI?, and OXLUMO? ? ? Advanced Vutrisiran toward Market with Positive Results from HELIOS-A Phase 3 Study and Submission of New Drug Application (NDA) with U.S. Food and Drug Administr |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No.) |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICA |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 2, 2021 |
DEFA14A 1 d19975ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy |
|
| April 2, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| February 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No |
|
| February 11, 2021 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity − Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Million, Respectively – − Achieved Regulatory Approvals of OXLUMO™ in the EU and U.S. and Leqvio®, by Partner Novartis, in the EU – – Launched “Alnylam P5x25” Strategy |
|
| February 11, 2021 |
Exhibit 10.20 CHANGE IN CONTROL AGREEMENT This Change in Control Agreement (“Agreement”) is made as of the 2nd day of November 2020 by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and John M. Maraganore, Ph.D. (the “Executive”). 1.Purpose. The Company considers it essential to the best interests of its stockholders to promote and preserve the continuous employ |
|
| February 11, 2021 |
S-8 1 d114010ds8.htm S-8 As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 77-0602661 (State or Other Jurisdiction of Incor |
|
| February 11, 2021 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Ownership Percentage Jurisdiction of Organization Alnylam U.S., Inc. 100% Delaware Alnylam Securities Corporation 100% Massachusetts Sirna Therapeutics, Inc. 100% Delaware Alnylam Austria GmbH 100% Austria Alnylam Belgium BVBA 100% Belgium Alnylam Brasil Farmaceutica Ltda 99% Brazil Alnylam (Bermuda) Ltd. 100% Bermuda Alnylam Canada ULC 100% Canada |
|
| February 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM |
|
| February 11, 2021 |
Exhibit 10.12 Alnylam Pharmaceuticals, Inc. Annual Incentive Program Purpose The People, Culture and Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (“Alnylam”) has recommended and the Board has approved this Annual Incentive Program (the “Bonus Plan”) to incent and reward eligible employees of Alnylam or any of its affiliates (subj |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Alnylam Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 02043Q107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 11, 2021 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years – New 5-Year Strategy Represents Alnylam’s Commitment to Delivering Transformative Rare and Prevalent Dise |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 (January 10, 2021) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Inco |
|
| November 5, 2020 |
Exhibit 10.1 EXECUTION COPY CO-DEVELOPMENT AGREEMENT By and between Alnylam Pharmaceuticals, Inc., BXLS V Bodyguard – PCP L.P. AND BXLS Family Investment Partnership V – ESC L.P. Dated August 15, 2020 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOUL |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEU |
|
| November 5, 2020 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ALNYLAM PHARMACEUTICALS, INC. (formerly Alnylam Holding Co.) 1 Table of Contents Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 4 1.5 Voting List 4 1.6 Quorum 5 1.7 Adjournments 5 1.8 Voting and Proxies 5 1.9 Action at Meeting 5 1.10 Nomination of Directors. 6 1.11 Notice of |
|
| November 5, 2020 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2020 ONPATTRO® Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.S. Growth, with More Than 1,150 Patients on Commercial Product Worldwide – − Achieved Third Quarter 2020 GIVLAARI® Global Net Product Revenue of $16.7 Million, with |
|
| November 5, 2020 |
Exhibit 10.2 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), is entered into as of August 15, 2020, among Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and Wilmington Trust, National Association, solely in its capacity as administrative agent (the “Administrative Agent”) |
|
| November 5, 2020 |
Exhibit 10.4 August 26, 2020 Barry E. Greene [**] Street [**] Dear Barry: In connection with your resignation from your position as President of Alnylam Pharmaceuticals, Inc. (the “Company”) as of September 30, 2020, the consulting obligations you have agreed to undertake, and the extension of your non-compete and non-solicitation obligations through September 30, 2022, this letter agreement summa |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| November 5, 2020 |
Exhibit 10.3 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of the 30th day of September, 2020 (the “Effective Date”) by and between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (“Landlord”), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). R E C I T A L S A. Landlord and Tenant entered into that certain Lease dated April |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 (September 30, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris-diction of In |
|
| August 20, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2020 (August 15, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris-diction of Incor |
|
| August 6, 2020 |
Exhibit 10.3 CREDIT AGREEMENT dated as of April 10, 2020 among ALNYLAM PHARMACEUTICALS, INC., as the Borrower, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Administrative Agent TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms 1 1.02 Other Interpretive |
|
| August 6, 2020 |
Exhibit 10.6 AMENDMENT TO ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN C. The Alnylam Pharmaceuticals, Inc. Amended and Restated 2004 Employee Stock Purchase Plan (as amended, the “Plan”) is hereby amended by the Board of Directors of Alnylam Pharmaceuticals, Inc. (the “Company”), subject to approval of the Company’s stockholders, to, among other things, inc |
|
| August 6, 2020 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity − Achieved Second Quarter 2020 ONPATTRO® Global Net Product Revenues of $66.5 Million, with More Than 1,050 Patients on Commercial Product Worldwide – − Achieved Second Quarter 2020 GIVLAARI® Global Net Product Revenues of $11.0 Million with More Than 100 Patients on Commercial |
|
| August 6, 2020 |
Exhibit 10.1 PATENT CROSS-LICENSE AGREEMENT between DICERNA PHARMACEUTICALS, INC. and ALNYLAM PHARMACEUTICALS, INC. April 3, 2020 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. ACTIVE/104 |
|
| August 6, 2020 |
Exhibit 10.5 SECOND AMENDMENT TO ALNYLAM PHARMACEUTICALS, INC. 2018 STOCK INCENTIVE PLAN A. The Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan (the “Plan”) is hereby amended by the Board of Directors of Alnylam Pharmaceuticals, Inc. (the “Company”), subject to approval of the Company’s stockholders, to, among other things, increase the aggregate number of shares authorized for issuance un |
|
| August 6, 2020 |
Alnylam Announces Planned Transition of Barry Greene, President Exhibit 99.2 Alnylam Announces Planned Transition of Barry Greene, President - Greene to Pursue New Opportunities at End-Q3, While Remaining a Consultant for Up to Two Years to Ensure Orderly Transition - - Yvonne Greenstreet to be Named President and Chief Operating Officer; Company Initiates Search for a Chief Commercial Officer - CAMBRIDGE, Mass.-(BUSINESS WIRE)-August 6, 2020-Alnylam Pharmaceu |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| August 6, 2020 |
Exhibit 10.2 PURCHASE AND SALE AGREEMENT dated as of April 10, 2020 between ALNYLAM PHARMACEUTICALS, INC. and BX BODYGUARD ROYALTIES L.P. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED Tab |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 (August 3, 2020) Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Ide |
|
| June 5, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 5, 2020 Registration No. |
|
| June 5, 2020 |
EX-4.2 EXHIBIT 4.2 EXECUTION VERSION STOCK PURCHASE AGREEMENT BY AND AMONG THE INVESTORS LISTED HEREIN AND ALNYLAM PHARMACEUTICALS, INC. DATED AS OF APRIL 10, 2020 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 4 2. Purchase and Sale of Common Stock 4 2.1 Purchase and Sale 4 2.2 Tax Treatment 5 3. Closing; Deliveries 5 3.1 Closing 5 3.2 Deliver |
|
| May 11, 2020 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 (May 6, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris-diction of Incorporatio |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 675 |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICA |
|
| May 6, 2020 |
EX-99.1 2 a52215004ex991.htm EXHIBIT 99.1 Exhibit 99.1 Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2020 ONPATTRO® Net Product Revenues of $66.7 Million with More Than 950 Patients on Commercial Product Worldwide – − Achieved First Quarter 2020 GIVLAARI® Net Product Revenues of $5.3 Million with More Than 50 Pat |
|
| April 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 (April 10, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorpor |
|
| April 13, 2020 |
EX-99.1 Exhibit 99.1 Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics – RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and Drug Development Today with Potential to Transform Lives of Patients – – Blackstone Provides a Customized Investment at Scale to Enable Alnylam to Achieve Sel |
|
| April 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 (April 3, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorporat |
|
| April 6, 2020 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Dicerna Pharmaceuticals, Inc. Media: Amy Trevvett, Dicerna Pharmaceuticals, Inc. +1 617-612-6253 [email protected] Investors: Lauren Stival, Stern Investor Relations, Inc. +1 212-362-1200 [email protected] Alnylam and Dic |
|
| March 24, 2020 |
ALNY / Alnylam Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A 1 d857049ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| March 23, 2020 |
DEF 14A 1 d857049ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 (February 26, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of In |
|
| February 13, 2020 |
Exhibit 10.50 Amendment to License and Collaboration Agreement This AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), dated as of November 22, 2019, is entered into between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and The Medicines Company, a corporation organized and existing under the laws of Delaw |
|
| February 13, 2020 |
As filed with the Securities and Exchange Commission on February 13, 2020 As filed with the Securities and Exchange Commission on February 13, 2020 Registration No. |
|
| February 13, 2020 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Ownership Percentage Jurisdiction of Organization Alnylam U.S., Inc. 100% Delaware Alnylam Securities Corporation 100% Massachusetts Sirna Therapeutics, Inc. 100% Delaware Alnylam Austria GmbH 100% Austria Alnylam Belgium BVBA 100% Belgium Alnylam Brasil Farmaceutica Ltda 99% Brazil Alnylam (Bermuda) Ltd. 100% Bermuda Alnylam Canada ULC 100% Canada |
|
| February 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM |
|
| February 13, 2020 |
Amended and Restated Bylaws of the Registrant, as amended Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ALNYLAM PHARMACEUTICALS, INC. (formerly Alnylam Holding Co.) ACTIVE/98617806.5 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors. 3 1.11 N |
|
| February 13, 2020 |
Amended and Restated Annual Incentive Program Exhibit 10.10 Alnylam Pharmaceuticals, Inc. Annual Incentive Program Purpose The Compensation Committee of the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (“Alnylam”) has recommended and the Board has approved this Annual Incentive Program (the “Bonus Plan”) to incent and reward eligible employees of Alnylam or any of its affiliates (subject to applicable local laws) (collec |
|
| February 13, 2020 |
Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Alnylam Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorpora |
|
| February 12, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Alnylam Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 02043Q107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 12, 2020 |
ALNY / Alnylam Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01196-alnylampharmaceutica.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Alnylam Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 02043Q107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate bo |
|
| February 6, 2020 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity − Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively – − As of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients World |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2020 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| January 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 (January 12, 2020) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Inco |
|
| January 13, 2020 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Joshua Brodsky (Investors) 617-551-8276 Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates – Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Preliminary Global Net Product Rev |
|
| November 20, 2019 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Joshua Brodsky (Investors) 617-551-8276 Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA) – GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Signifi |
|
| November 20, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 ( November 20, 2019 ) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction o |
|
| October 31, 2019 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide – − Initiated APOLLO-B Phase 3 Study of Patisiran for the Treatment of Hereditary and Wild-Type ATTR Amyl |
|
| October 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 Alnylam Pharmaceuticals, Inc. Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| October 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEU |
|
| October 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2019 (September 27, 2019) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Inc |
|
| August 6, 2019 |
Exhibit 99.1 Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity − Achieved Second Quarter 2019 ONPATTRO® Global Net Product Revenues of $38.2 Million with More Than 500 Patients on Commercial Product Worldwide – − Reported Positive Results from ENVISION Phase 3 Study of Givosiran, Submitted Regulatory Filings in the U.S. and EU, and Received |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Juris- diction of Incorporation) (Commiss |
|
| August 6, 2019 |
Confidential Exhibit 10.3 AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENT THIS AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENT (this “Agreement”), dated as of April 8, 2019 (the “Amendment No. 3 Effective Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporatio |
|
| August 6, 2019 |
Confidential Exhibit 10.5 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between GENZYME CORPORATION AND ALNYLAM PHARMACEUTICALS, INC. Dated as of April 8, 2019 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE C |
|
| August 6, 2019 |
Exhibit 10.1 ALNYLAM PHARMACEUTICALS, INC. 2018 STOCK INCENTIVE PLAN 1.Purpose The purpose of this 2018 Stock Incentive Plan (the “Plan”) of Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the |
|
| August 6, 2019 |
Exhibit 10.2 ALNYLAM PHARMACEUTICALS, INC. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan Name of Grantee:[] No. of Performance Stock Units[] Grant Date:[] Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Perf |
|
| August 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36407 ALNYLAM PHARMACEUTICAL |
|
| August 6, 2019 |
Exhibit 10.8 Confidential MASTER AGREEMENT between ALNYLAM PHARMACEUTICALS, INC. and REGENERON PHARMACEUTICALS, INC. Dated as of April 8, 2019 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSE |
|
| August 6, 2019 |
Confidential Exhibit 10.4 AMENDED AND RESTATED ALN-AT3 Global License Terms dated as of April 8, 2019 by and between ALNYLAM PHARMACEUTICALS, INC. and GENZYME CORPORATION Confidential CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE CO |
|
| August 6, 2019 |
Confidential Exhibit 10.7 INVESTOR AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. AND ALNYLAM PHARMACEUTICALS, INC. Dated as of APRIL 8, 2019 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF |
|
| August 6, 2019 |
Exhibit 10.6 STOCK PURCHASE AGREEMENT BY AND BETWEEN REGENERON PHARMACEUTICALS, INC. AND ALNYLAM PHARMACEUTICALS, INC. DATED AS OF APRIL 8, 2019 ACTIVE/97613778.18 TABLE OF CONTENTS Page 1. Definitions1 1.1 Defined Terms1 1.2 Additional Defined Terms3 2. Purchase and Sale of Common Stock or Preferred Stock4 3. Closing Date; Deliveries5 3.1 Closing Date5 3.2 Deliveries5 4. Representations and Warra |
|
| July 11, 2019 |
EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer – Announces Planned Appointment of Jeff Poulton – – Manmeet S. Soni to Resign After a Transition Period – CAMBRIDGE, Mass., July 11, 2019 – Alnylam Pharmaceuticals, In |
|
| July 11, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2019 (July 8, 2019) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of In |
|
| May 21, 2019 |
Entry into a Material Definitive Agreement, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2019 (May 21, 2019) Alnylam Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36407 77-0602661 (State or Other Jurisdiction of Incorpor |
|
| May 3, 2019 |
ALNY / Alnylam Pharmaceuticals, Inc. / Sanofi - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 02043Q107 (CUSIP Number) May 2, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
